Natera Q1 revenue $241.8M (+24.5% YoY), raises 2023 revenue guidance to $995M-$1.015B

Natera, Inc.

2023-Q1 EPS reported -$1.23 revenue$241,756,000

Total revenue $241.8M (+24.5% YoY); product revenue $237.8M (+25.2% YoY).
Tests processed 626,200 (+28% YoY); oncology tests 71,000 (+102% YoY).
Net loss $136.9M ($1.23/share) vs $138.6M ($1.45) in prior year; loss per share improved.
Raised 2023 revenue guidance to $995M-$1.015B from prior $990M-$1.0B; gross margin guidance unchanged at 41%-44%.
Secured Medicare coverage for Prospera heart transplant test and first commercial coverage for Signatera (Blue Shield CA).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Natera, Inc. reported first quarter ended March 31, 2023 results: revenue $241.8 million, net income net loss of $136.9 million, EPS ($1.23) per diluted share. Guidance raised.

Period: first quarter ended March 31, 2023
Revenue: $241.8 million
Net income: net loss of $136.9 million
EPS: ($1.23) per diluted share
Guidance: raised
Result: reported results

Exact text from the filing

in cell-free DNA testing , today reported financial results for the first quarter ended March 31, 2023. Recent Strategic and Financial Highlights ● Generated total revenues of $241.8 million in the first quarter of 2023, compared to $194.1 million in the first quarter of 2022, an increase of 24.5%. Product revenues grew 25.2% over the same period. ● Processed

View on SEC.gov

Browse all earnings releases →

Natera, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-057710

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.